SynthesisWorld journal of gastroenterology2010
Remission induction and maintenance effect of probiotics on ulcerative colitis: a meta-analysis.
Synthesis in World journal of gastroenterology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 4 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Probiotics combined with aminosalicylic acid affiliates remission of ulcerative colitis: a meta-analysis of randomized controlled trial.Bioscience reports · 2019Pooled it
- Evidence-based clinical practice guidelines for inflammatory bowel disease.Journal of gastroenterology · 2018Guideline
- Methodological Quality Assessment of Meta-Analyses and Systematic Reviews of Probiotics in Inflammatory Bowel Disease and Pouchitis.PloS one · 2016Pooled it
- Probiotic treatments for induction and maintenance of remission in inflammatory bowel diseases: a meta-analysis of randomized controlled trials.Clinical journal of gastroenterology · 2014Pooled it
- VSL#3Nutrients · 2026Trial
- Does Multi-Strain Probiotic Supplementation Impact the Effort Capacity of Competitive Road Cyclists?International journal of environmental research and public health · 2022Trial
- A randomised, double-blind, placebo-controlled trial of a multi-strain probiotic in patients with asymptomatic ulcerative colitis and Crohn's disease.Inflammopharmacology · 2019Trial
- Effectiveness of probiotic therapy for the prevention of relapse in patients with inactive ulcerative colitis.World journal of gastroenterology · 2015Trial
- Genomic Assessment, Metabolic Profile Mapping, and Anti-Helicobacter pylori Activity of Lactococcus lactis SK2-659 from Thai Fermented Green Mustard (Pak-kad-dong).Probiotics and antimicrobial proteins · 2026Article
- Bile Derivative T3K Ameliorates Colitis by Regulating the Intestinal Microbiota-Bile Acid Axis.Pharmaceutics · 2025Article
- The Impact of Probiotics on Clinical Outcomes in Diverticular Disease: A Systematic Review and Meta-Analysis.Journal of clinical medicine · 2025Review
- Probiotics and inflammatory bowel disease: an umbrella meta-analysis of relapse, recurrence, and remission outcomes.Nutrition & metabolism · 2025Review
- Combining mucosal microbiome and host multi-omics data shows prognostic potential in paediatric ulcerative colitis.Nature communications · 2025Article
- Screening Probiotics for Anti-Foods (Basel, Switzerland) · 2024Article
- Current Knowledge about Gastric Microbiota with Special Emphasis onCurrent issues in molecular biology · 2024Review
- The Role of the Microbiome in the Pathogenesis and Treatment of Ulcerative Colitis-A Literature Review.Biomedicines · 2023Review
- Arecoline aggravates acute ulcerative colitis in mice by affecting intestinal microbiota and serum metabolites.Frontiers in immunology · 2023Article
- Ginsenoside Rg1 Alleviates Acute Ulcerative Colitis by Modulating Gut Microbiota and Microbial Tryptophan Metabolism.Frontiers in immunology · 2022Article
- The interplay betweenFrontiers in cellular and infection microbiology · 2022Review
- Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease.International journal of molecular sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the induction of remission and maintenance effects of probiotics for ulcerative colitis.
methodsInformation was retrieved from MEDLINE, EMBASE, and the Cochrane Controlled Trials Register. The induction of remission and promotion of maintenance were compared between probiotics treatment and non-probiotics treatment in ulcerative colitis.
resultsThirteen randomized controlled studies met the selection criteria. Seven studies evaluated the remission rate, and eight studies estimated the recurrence rate; two studies evaluated both remission and recurrence rates. Compared with the non-probiotics group, the remission rate for ulcerative colitis patients who received probiotics was 1.35 (95% CI: 0.98-1.85). Compared with the placebo group, the remission rate of ulcerative colitis who received probiotics was 2.00 (95% CI: 1.35-2.96). During the course of treatment, in patients who received probiotics for less than 12 mo compared with the group treated by non-probiotics, the remission rate of ulcerative colitis was 1.36 (95% CI: 1.07-1.73). Compared with the non-probiotics group, the recurrence rate of ulcerative colitis patients who received probiotics was 0.69 (95% CI: 2.47-1.01). In the mild to moderate group who received probiotics, compared to the group who did not receive probiotics, the recurrence rate was 0.25 (95% CI: 0.12-0.51). The group who received Bifidobacterium bifidum treatment had a recurrence rate of 0.25 (95% CI: 0.12-0.50) compared with the non-probiotics group.
conclusionProbiotic treatment was more effective than placebo in maintaining remission in ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.